Cargando…

DDRE-18. THE MITOCHONDRIAL PYRUVATE CARRIER—A METABOLIC TARGET OF MALIGNANT GLIOMA

Metabolic reprogramming has been recognized as crucial to the survival and proliferation of cancer cells through the reduction of glucose oxidation (the Warburg effect) and diversion of pyruvate and glycolytic metabolites to fuel anabolic processes. The mitochondrial pyruvate carrier (MPC) protein c...

Descripción completa

Detalles Bibliográficos
Autores principales:	Tiburcio, Patricia, Murnyak, Balazs, Coffman, Kimberly, Huang, Eric
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2021
Materias:	Supplement Abstracts
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7992274/ http://dx.doi.org/10.1093/noajnl/vdab024.040

Ejemplares similares

DDRE-16. CYSTEINE IS AN ESSENTIAL AMINO ACID IN GLIOMAS
por: Ruiz-Rodado, Victor, et al.
Publicado: (2021)

DDRE-21. THE FUNCTION OF MITOCHONDRIAL OSMR IN GLIOMA STEM CELL RESPIRATION AND GLIOBLASTOMA PATHOGENESIS
por: Jahani-Asl, Arezu, et al.
Publicado: (2021)

DDRE-30. THERAPEUTIC TARGETING OF DISRUPTED METABOLIC STATE IN DIFFUSE INTRINSIC PONTINE GLIOMA
por: Mbah, Nneka, et al.
Publicado: (2021)

DDRE-32. THERAPEUTIC TARGETING OF A NOVEL METABOLIC ADDICTION IN DIFFUSE MIDLINE GLIOMA
por: Pal, Sharmistha, et al.
Publicado: (2021)

DDRE-09. THERAPEUTIC TARGETING OF PURINE METABOLISM IN DIPG
por: Mersich, Ian, et al.
Publicado: (2021)

DDRE-08. NRF2/GLUTATHIONE METABOLISM AS A NOVEL THERAPEUTIC TARGET FOR IDH1-MUTATED GLIOMA
por: Liu, Yang, et al.
Publicado: (2021)

DDRE-33. MELATONIN AS A MASTER METABOLIC SWITCH FOR GLIOBLASTOMA
por: Fernandez-Gil, Beatriz Irene, et al.
Publicado: (2021)

DDRE-31. FEASIBILITY AND BIOLOGIC ACTIVITY OF A KETOGENIC / INTERMITTENT FASTING DIET IN GLIOMA PATIENTS
por: Schreck, Karisa, et al.
Publicado: (2021)

DDRE-20. TARGETING SPHINGOLIPID PATHWAY REVEALS VULNERABILITY IN IDH1(MUT) GLIOMA
por: Dowdy, Tyrone, et al.
Publicado: (2021)

DDRE-12. HETEROGENOUS RESPONSE OF IDH-MUTANT AND IDH-WT GLIOMA TO NAMPT INHIBITION
por: Rahman, Masum, et al.
Publicado: (2021)

DDRE-34. TARGETING RESISTANCE IN MEDULLOBLASTOMA
por: Chang, Simone, et al.
Publicado: (2021)

DDRE-24. TARGETING PURINE METABOLISM TO OVERCOME GLIOBLASTOMA THERAPY RESISTANCE
por: Zhou, Weihua, et al.
Publicado: (2021)

DDRE-29. DE NOVO PYRIMIDINE SYNTHESIS IS A TARGETABLE VULNERABILITY IN IDH-MUTANT GLIOMA
por: Shi, Diana D, et al.
Publicado: (2021)

DDRE-22. TARGETING SERINE SYNTHESIS IN BRAIN METASTASIS
por: Ngo, Bryan, et al.
Publicado: (2021)

DDRE-11. TARGETING FATTY ACID BIOSYNTHESIS IN GLIOBLASTOMA
por: Eyme, Katharina M, et al.
Publicado: (2021)

DDRE-27. IDH MUTATED GLIOMAS PROMOTE EPILEPTOGENESIS VIA D-2-HYDROXYGLUTARATE DEPENDENT MTOR HYPERACTIVATION
por: Mortazavi, Armin, et al.
Publicado: (2021)

DDRE-17. A PHASE I CLINICAL TRIAL OF DOSE-ESCALATED METABOLIC THERAPY COMBINED WITH CONCOMITANT RADIATION THERAPY IN HIGH-GRADE GLIOMA
por: Porper, Keren, et al.
Publicado: (2021)

DDRE-25. INVESTIGATING MITOCHONDRIAL SLC25A TRANSPORTERS INVOLVED IN SUPPORTING BRAIN TUMOUR METABOLISM AND SURVIVAL UNDER HYPOXIC CONDITIONS
por: Eales, Katherine, et al.
Publicado: (2021)

DDRE-15. THE EVOLUTIONARY ENIGMA OF FATTY ACID DESATURATION IN GLIOBLASTOMA
por: Oatman, Nicole, et al.
Publicado: (2021)

DDRE-07. FATTY ACID SYNTHESIS IS REQUIRED FOR BREAST CANCER BRAIN METASTASIS
por: Ferraro, Gino, et al.
Publicado: (2021)

DDRE-13. INHIBITION OF EXTRACELLULAR CARBONIC ANHYDRASES INHIBITS GLIOBLASTOMA CELL INVASION
por: Proescholdt, Martin, et al.
Publicado: (2021)

DDRE-26. THE IMMUNO-METABOLIC ENZYME FASN PREVENTS CANCER-CELL INTRINSIC TYPE I INTERFERON RESPONSES IN GLIOBLASTOMA
por: De Martino, Mara, et al.
Publicado: (2021)

DDRE-14. DE-NOVO PURINE BIOSYNTHESIS IS A MAJOR DRIVER OF CHEMORESISTANCE IN GLIOBLASTOMA
por: Ahmed, Atique
Publicado: (2021)

DDRE-28. MECHANISTIC AND THERAPEUTIC LINKS BETWEEN PURINE BIOSYNTHESIS AND DNA DAMAGE IN GLIOBLASTOMA
por: Scott, Andrew, et al.
Publicado: (2021)

DDRE-01. METABOLIC PLASTICITY AND HETEROGENEITY IN IDH1MUT CELL LINES PRODUCES RESISTANCE TO GLUTAMINASE INHIBITION BY CB839
por: Larion, Mioara, et al.
Publicado: (2021)

DDRE-10. METABOLIC TARGETING OF HUMAN GLIOBLASTOMA USING 5-AMINOLEVULINIC ACID (ALA)-MEDIATED SONODYNAMIC THERAPY: A FIRST-IN-HUMAN STUDY
por: Marcus, Stuart, et al.
Publicado: (2021)

DDRE-02. SMOOTHENED-ACTIVATING LIPIDS DRIVE RESISTANCE TO CDK4/6 INHIBITION IN HEDGEHOG-ASSOCIATED MEDULLOBLASTOMA
por: Daggubati, Vikas, et al.
Publicado: (2021)

DDRE-19. PHASE 0/I TRIAL OF MYCOPHENOLATE MOFETIL COMBINED WITH RADIATION TO OVERCOME GLIOBLASTOMA TREATMENT RESISTANCE BY TARGETING DE-NOVO PURINE METABOLISM
por: Umemura, Yoshie, et al.
Publicado: (2021)

DDRE-06. REGULATION OF TUMOR MICROENVIRONMENT VIA ENDOTHELIAL-TO-MESENCHYMAL TRANSITION BLOCKADE IN GLIOBLASTOMA-ASSOCIATED BRAIN ENDOTHELIAL CELLS
por: Marin’ Ramos, Nagore I, et al.
Publicado: (2021)

DDRE-05. STEAROYL COA DESATURASE IS ESSENTIAL FOR REGULATION OF ENDOPLASMIC RETICULUM HOMEOSTASIS AND TUMOR GROWTH IN GLIOBLASTOMA CANCER STEM CELLS
por: Park, David, et al.
Publicado: (2021)

DDRE-03. IDH1-MUTANT GBM CELLS ARE HIGHLY SENSITIVE TO COMBINATION OF KDM6A/B AND HDAC INHIBITORS
por: Kayabölen, Alişan, et al.
Publicado: (2021)

DDRE-04. THE COMBINED TREATMENT OF L-ASPARAGINASE AND 6-DIAZO-5-OXO-L-NORLEUCINE INHIBIT THE PROLIFERATION OF TEMOZOLOMIDE-SENSITIVE OR RESISTANT GLIOBLASTOMA CELLS
por: Ohba, Shigeo, et al.
Publicado: (2021)

DDRE-23. A COMPREHENSIVE CHARACTERIZATION OF THE GBM LIPIDOME REVEALS A MOLECULARLY-DEFINED SUB-GROUP WITH HEIGHTENED SENSITIVITY TO LIPID PEROXIDATION INDUCED CELL DEATH
por: Morrow, Danielle, et al.
Publicado: (2021)

The Multifaceted Pyruvate Metabolism: Role of the Mitochondrial Pyruvate Carrier
por: Zangari, Joséphine, et al.
Publicado: (2020)

ETMM-06. ELEVATED MITOCHONDRIAL TOM20 EXPRESSION SUPPRESSES GLIOMA MALIGNANCY BY ENHANCING OXIDATIVE PHOSPHORYLATION
por: Li, Mao, et al.
Publicado: (2021)

BIMG-16. TRACKING TTFIELDS-INDUCED ALTERATIONS IN GLIOBLASTOMA METABOLISM WITH [18F]DASA-23, A NON-INVASIVE PROBE OF PYRUVATE KINASE M2 (PKM2)
por: Patel, Chirag, et al.
Publicado: (2021)

BIMG-13. A NOVEL RADIOPHARMACEUTICAL ([(18)F]DASA-23) TO MONITOR PYRUVATE KINASE M2 INDUCED GLYCOLYTIC REPROGRAMMING IN GLIOBLASTOMA
por: Beinat, Corinne, et al.
Publicado: (2021)

TBMT-02. APOLLO: RAMAN-BASED PATHOLOGY OF MALIGNANT GLIOMA
por: Lita, Adrian, et al.
Publicado: (2021)

STMO-7 Usefulness of NU-KNIT in retractorless surgery for malignant glioma
por: Yamanaka, Yuji, et al.
Publicado: (2021)

ET-8 Integrated diagnostic approach to predict prognosis for malignant gliomas
por: Isoda, Masataka, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_hle73nvcpnb8r0s88j3l45588v